Related Experiment Video

Updated: May 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Emerging tyrosine kinase inhibitors for head and neck cancer

Paolo Bossi1, Laura Locati, Lisa Licitra

  • 1Fondazione IRCCS Istituto Nazionale dei Tumori , Via Venezian 1, 20133 Milan , Italy +39 02 23902150 ; +39 02 23903769 ; paolo.bossi@istitutotumori.mi.it.

Expert Opinion on Emerging Drugs
|October 8, 2013
PubMed
Abstract

Insights

Tyrosine kinase inhibitors (TKIs) show limited efficacy and increased toxicity when added to chemotherapy for recurrent head and neck squamous cell cancer. Novel strategies are needed for better outcomes in HNSCC treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Background:

  • Conventional treatments for head and neck squamous cell cancer (HNSCC) have limitations in efficacy and toxicity.
  • Current treatment modalities include surgery, chemoradiotherapy, and biological agents.

Purpose of the Study:

  • To evaluate tyrosine kinase inhibitors (TKIs) in HNSCC treatment.
  • To assess the optimal timing and disease setting for TKI application.
  • To explore alternative therapeutic strategies for HNSCC.

Main Methods:

  • Review of clinical trials involving TKIs in HNSCC.
  • Analysis of TKI efficacy and toxicity in different treatment settings.
  • Evaluation of TKI combinations and novel therapeutic approaches.

Main Results:

  • TKIs combined with chemotherapy in recurrent/metastatic HNSCC show significant side effects and limited efficacy gains.
  • Optimal use of TKIs may be in neoadjuvant, adjuvant, or concurrent chemoradiation settings.
  • Challenges include patient characteristics, treatment resistance, and side effect management.

Conclusions:

  • TKIs are not optimal as add-on therapy to chemotherapy in recurrent/metastatic HNSCC due to toxicity and lack of efficacy.
  • Targeted agents may be more effective when used before, after, or concurrently with local-regional treatments.
  • Future research should focus on irreversible pan-HER inhibitors, combination therapies, and predictive biomarkers.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...